AUTHOR=Qiao Guanzhong , Feng Lili , Li Zhenhui , Wu Qiong , Liu Yulin , Zhao Jie , Jiang Hao , Zhao Ke , Cui Yanfen , Jiang Huijie 

TITLE=Deep learning based on MRI for assessing the prognostic value of lateral lymph nodes in rectal cancer

JOURNAL=Frontiers in Oncology

VOLUME=Volume 15 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1681939

DOI=10.3389/fonc.2025.1681939

ISSN=2234-943X

ABSTRACT=ObjectivesAccurate preoperative evaluation of positive lateral lymph node (LLN) is crucial for optimizing treatment strategies in rectal cancer. Traditional methods, such as MRI T2-weighted imaging (T2WI), face limitations like interobserver variability and difficulty detecting small or occult metastases. Deep learning (DL) may provide a more efficient and precise alternative.MethodsIn this multicenter, retrospective study, images from 1,000 patients across five centers were annotated to train a DL model for identifying and segmenting LLN. The model was tested on images from 480 patients in a validation cohort. Kaplan-Meier analysis compared disease-free survival (DFS) and overall survival (OS) between LLN-positive and LLN-negative groups, while Cox regression identified prognostic factors for DFS and OS.ResultsThe DL model achieved an accuracy of 87.5% and a specificity of 73.8% in predicting LLN positivity, demonstrating high diagnostic performance. Both univariate and multivariate Cox regression analyses identified LLN status, circumferential resection margin (CRM), and tumor downstaging (TD) as independent prognostic factors. Kaplan-Meier analysis showed patients with positive LLNs had worse outcomes, with 3-year DFS of 57.66% vs. 81.66%, and 5-year OS of 61.62% vs. 84.82% compared to LLN-negative patients.ConclusionsThe DL model effectively predicts positive LLNs, offering an efficient alternative to traditional methods and supporting preoperative decision-making. Its clinical implementation could enhance risk stratification and personalize therapeutic strategies for rectal cancer patients.